Blood Test Identifies AML Patients at Risk of Posttransplant Relapse
National Institutes of Health
A small portion of acute myeloid leukemia patients in remission showed persisting mutations, which predicted their risk of death from cancer relapse
Microfluidic device uses lactate levels in circulating single cells as a biomarker to detect and classify active tumor cells
AI algorithms and imaging biomarkers may amp up the prediction accuracy of risk models
Machine learning model combines fusion gene expression, serum PSA level, and Gleason score to accurately predict cancer recurrence